FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386443102> ?p ?o ?g. }

• W4386443102 endingPage "34090" @default.
• W4386443102 startingPage "34084" @default.
• W4386443102 abstract "In tropical and subtropical areas, malaria stands as a profound public health challenge, causing an estimated 247 million cases worldwide annually. Given the absence of a viable vaccine, the timely and effective treatment of malaria remains a critical priority. However, the growing resistance of parasites to currently utilized drugs underscores the critical need for the identification of new antimalarial therapies. Here, we aimed to identify potential new drug candidates against Plasmodium falciparum, the main causative agent of malaria, by analyzing the transcriptomes of different life stages of the parasite and identifying highly expressed genes. We searched for genes that were expressed in all stages of the parasite’s life cycle, including the asexual blood stage, gametocyte stage, liver stage, and sexual stages in the insect vector, using transcriptomics data from publicly available databases. From this analysis, we found 674 overlapping genes, including 409 essential ones. By searching through drug target databases, we discovered 70 potential drug targets and 75 associated bioactive compounds. We sought to expand this analysis to similar compounds to known drugs. So, we found a list of 1557 similar compounds, which we predicted as actives and inactives using previously developed machine learning models against five life stages of Plasmodium spp. From this analysis, two compounds were selected, and the reactions were experimentally evaluated. The compounds HSP-990 and silvestrol aglycone showed potent inhibitory activity at nanomolar concentrations against the P. falciparum 3D7 strain asexual blood stage. Moreover, silvestrol aglycone exhibited low cytotoxicity in mammalian cells, transmission-blocking potential, and inhibitory activity comparable to those of established antimalarials. These findings warrant further investigation of silvestrol aglycone as a potential dual-acting antimalarial and transmission-blocking candidate for malaria control." @default.
• W4386443102 created "2023-09-06" @default.
• W4386443102 creator A5025873298 @default.
• W4386443102 creator A5034619264 @default.
• W4386443102 creator A5045712970 @default.
• W4386443102 creator A5049859188 @default.
• W4386443102 creator A5055347627 @default.
• W4386443102 creator A5058368047 @default.
• W4386443102 creator A5068574898 @default.
• W4386443102 creator A5068579674 @default.
• W4386443102 creator A5071012302 @default.
• W4386443102 date "2023-09-05" @default.
• W4386443102 modified "2023-10-15" @default.
• W4386443102 title "Transcriptomics-Guided In Silico Drug Repurposing: Identifying New Candidates with Dual-Stage Antiplasmodial Activity" @default.
• W4386443102 cites W128681645 @default.
• W4386443102 cites W1935782451 @default.
• W4386443102 cites W1969503178 @default.
• W4386443102 cites W2035736772 @default.
• W4386443102 cites W2083280521 @default.
• W4386443102 cites W2084547321 @default.
• W4386443102 cites W2127733438 @default.
• W4386443102 cites W2146341019 @default.
• W4386443102 cites W2153369718 @default.
• W4386443102 cites W2429903483 @default.
• W4386443102 cites W2574342612 @default.
• W4386443102 cites W2593540423 @default.
• W4386443102 cites W2789605577 @default.
• W4386443102 cites W2790300533 @default.
• W4386443102 cites W2800834635 @default.
• W4386443102 cites W2888848653 @default.
• W4386443102 cites W2896002881 @default.
• W4386443102 cites W2938448257 @default.
• W4386443102 cites W3025733956 @default.
• W4386443102 cites W30716843 @default.
• W4386443102 cites W3160521566 @default.
• W4386443102 cites W3182055317 @default.
• W4386443102 cites W3210331473 @default.
• W4386443102 cites W4211051628 @default.
• W4386443102 doi "https://doi.org/10.1021/acsomega.3c05138" @default.
• W4386443102 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37744849" @default.
• W4386443102 hasPublicationYear "2023" @default.
• W4386443102 type Work @default.
• W4386443102 citedByCount "0" @default.
• W4386443102 crossrefType "journal-article" @default.
• W4386443102 hasAuthorship W4386443102A5025873298 @default.
• W4386443102 hasAuthorship W4386443102A5034619264 @default.
• W4386443102 hasAuthorship W4386443102A5045712970 @default.
• W4386443102 hasAuthorship W4386443102A5049859188 @default.
• W4386443102 hasAuthorship W4386443102A5055347627 @default.
• W4386443102 hasAuthorship W4386443102A5058368047 @default.
• W4386443102 hasAuthorship W4386443102A5068574898 @default.
• W4386443102 hasAuthorship W4386443102A5068579674 @default.
• W4386443102 hasAuthorship W4386443102A5071012302 @default.
• W4386443102 hasBestOaLocation W43864431021 @default.
• W4386443102 hasConcept C103637391 @default.
• W4386443102 hasConcept C104317684 @default.
• W4386443102 hasConcept C114851261 @default.
• W4386443102 hasConcept C136764020 @default.
• W4386443102 hasConcept C150194340 @default.
• W4386443102 hasConcept C162317418 @default.
• W4386443102 hasConcept C203014093 @default.
• W4386443102 hasConcept C2775905019 @default.
• W4386443102 hasConcept C2778048844 @default.
• W4386443102 hasConcept C2778371730 @default.
• W4386443102 hasConcept C2778675580 @default.
• W4386443102 hasConcept C2780035454 @default.
• W4386443102 hasConcept C41008148 @default.
• W4386443102 hasConcept C54355233 @default.
• W4386443102 hasConcept C60644358 @default.
• W4386443102 hasConcept C70721500 @default.
• W4386443102 hasConcept C71928629 @default.
• W4386443102 hasConcept C74187038 @default.
• W4386443102 hasConcept C86803240 @default.
• W4386443102 hasConcept C98274493 @default.
• W4386443102 hasConcept C99389464 @default.
• W4386443102 hasConceptScore W4386443102C103637391 @default.
• W4386443102 hasConceptScore W4386443102C104317684 @default.
• W4386443102 hasConceptScore W4386443102C114851261 @default.
• W4386443102 hasConceptScore W4386443102C136764020 @default.
• W4386443102 hasConceptScore W4386443102C150194340 @default.
• W4386443102 hasConceptScore W4386443102C162317418 @default.
• W4386443102 hasConceptScore W4386443102C203014093 @default.
• W4386443102 hasConceptScore W4386443102C2775905019 @default.
• W4386443102 hasConceptScore W4386443102C2778048844 @default.
• W4386443102 hasConceptScore W4386443102C2778371730 @default.
• W4386443102 hasConceptScore W4386443102C2778675580 @default.
• W4386443102 hasConceptScore W4386443102C2780035454 @default.
• W4386443102 hasConceptScore W4386443102C41008148 @default.
• W4386443102 hasConceptScore W4386443102C54355233 @default.
• W4386443102 hasConceptScore W4386443102C60644358 @default.
• W4386443102 hasConceptScore W4386443102C70721500 @default.
• W4386443102 hasConceptScore W4386443102C71928629 @default.
• W4386443102 hasConceptScore W4386443102C74187038 @default.
• W4386443102 hasConceptScore W4386443102C86803240 @default.
• W4386443102 hasConceptScore W4386443102C98274493 @default.
• W4386443102 hasConceptScore W4386443102C99389464 @default.
• W4386443102 hasFunder F4320320997 @default.
• W4386443102 hasFunder F4320321091 @default.

• next